Current Valuation
N/A
As of July 29, 2025
Total Funding Raised
$51.5M
Last Round
Later Stage VC

$11.0M

Last Funding
Jul 2025

Funding date

Capital Efficiency
N/A

Valuation / Funding

Funding History & Valuation Timeline
Complete history of all funding rounds and valuation milestones

No funding history available

Funding data has not been imported for this company yet

Valuation Analysis

Current Valuation Metrics

Artax Biopharma is currently valued at N/A as of July 29, 2025. The company has raised a total of $51.5M in funding.

Investment Perspective

Artax Biopharma's valuation reflects investor confidence in the company's market position, growth potential, and ability to execute on its business model. Private market valuations are determined by primary funding rounds and secondary market transactions, which take into account financial performance, market conditions, and growth prospects.

Track Artax Biopharma Valuation Updates

Get notified when Artax Biopharma raises new funding or valuation changes

What is Artax Biopharma Worth in 2025?

As of 2025, Artax Biopharma is valued at N/A, based on the company's Later Stage VC funding round in July 29, 2025. This valuation positions Artax Biopharma as one of the leading private companies in the sector.

Artax Biopharma Valuation History

Artax Biopharma's funding history demonstrates steady growth and investor confidence.

How Artax Biopharma Valuation is Determined

Private company valuations like Artax Biopharma's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including:

  • Revenue growth and financial performance
  • Market opportunity and total addressable market (TAM)
  • Competitive positioning and market share
  • Management team strength and execution capability
  • Technology and intellectual property
  • Industry trends and investor sentiment

Artax Biopharma Valuation FAQs

Is Artax Biopharma profitable?

Artax Biopharma has not publicly disclosed its profitability status. Many high-growth private companies prioritize market expansion and user growth over profitability in their early stages.

How does Artax Biopharma's valuation compare to competitors?

Artax Biopharma is valued at N/A, positioning it as a major player in the space. Secondary market pricing and private market transactions provide ongoing validation of this valuation.

When will Artax Biopharma IPO?

Artax Biopharma has not announced plans for an initial public offering. Until an IPO, investors can access Artax Biopharma shares through secondary market platforms.